The recommended starting dose is 45 mg of ponatinib once daily. For the standard dose of 45 mg once daily, a 45 mg film-coated tablet is available. Treatment should be continued as long as the patient does not show evidence of disease progression or unacceptable toxicity.
Patients should be monitored for response according to standard clinical guidelines.
Discontinuing ponatinib should be considered if a complete haematologic response has not occurred by 3 months (90 days).
Method of administration: Ponatinib (Iclusig) is for oral use. The tablets should be swallowed whole. Patients should not crush or dissolve the tablets. Ponatinib (Iclusig) may be taken with or without food.
Patients should be advised not to swallow the desiccant canister found in the bottle.